Phase III KEYNOTE-564 trial: Keytruda after surgery reduced risk of recurrence or death by 32% in RCC

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Keytruda (pembrolizumab) demonstrated a statistically significant and clinically meaningful reduction in the risk of disease recurrence or death by 32% compared to placebo (HR=0.68 [95% CI, 0.53–0.87]; p=0.0010) as a potential adjuvant treatment of renal cell carcinoma at intermediate-high or high risk of recurrence following nephrectomy or following nephrectomy and resection of metastatic lesions. 

After a median follow-up of 24.1 months (14.9-41.5), Keytruda demonstrated a statistically significant and clinically meaningful reduction in the risk of disease recurrence or death by 32% compared to placebo (HR=0.68 [95% CI, 0.53–0.87]; p=0.0010).

Data from the phase III KEYNOTE-564 trial also demonstrated a 46% reduction in the risk of death with KEYTRUDA as compared to placebo (HR=0.54 [95% CI, 0.30–0.96]; p=0.0164). The trial will continue to evaluate OS, a key secondary endpoint.

The late-breaking results were presented in the plenary session of the 2021 American Society of Clinical Oncology annual meeting (Abstract #LBA5). 

Keytruda is approved in the U.S., Europe and Japan in combination with axitinib for the first-line treatment of patients with advanced RCC.

Table of Contents

YOU MAY BE INTERESTED IN

In April 2025, announcements from the two most influential biomedical agencies in the US, the FDA and the NIH, declared that both will seek to reduce and minimize animal-based testing and experimentation. These declarations sparked joy in some circles, and deep concern in others that was reflected in a 28% fall in the share price of Charles River Labs (NYSE: NYSE:CRL). 
Over the past three decades, cancer genetics has transformed precision oncology. Germline testing has advanced from single-gene Sanger sequencing to parallel sequencing of hundreds of genes, while tumor (somatic) testing has expanded with the rise of targeted therapies based on point mutations, copy number changes and other alterations. 

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login